Accéder au contenu
Merck

Intranasal flunisolide treatment in patients with non-allergic rhinitis.

International journal of immunopathology and pharmacology (2011-06-11)
A Varricchio, M Capasso, A De Lucia, F Avvisati, A M Varricchio, G Bettoncelli, G Ciprandi
RÉSUMÉ

Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation. Its treatment is still debated, intranasal corticosteroids may be an option. The present study is aimed at evaluating the effect of the use of intranasal flunisolide in patients with NAR, considering both clinical and cytological parameters. Sixty patients were treated with intranasal flunisolide (30) or saline solution (30) for 8 weeks. Symptom severity, turbinate size, and inflammatory cell counts were assessed, before and after treatment. Intranasal flunisolide induced a significant reduction of symptoms, turbinate size, and cellular infiltrate. Thus, intranasal flunisolide might be a therapeutic option for NAR.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Flunisolide, ≥97%